



**Governing Council
Sixty-fifth Session**

Lyon, 10–12 May 2023

Proposed Programme and Budget 2024–2025
Budget and Information Tables (**Revision 1**)

The Budget and Information Tables contained in this document replace pages 26–43 of Document GC/65/9 Proposed Programme and Budget 2024–2025.

BUDGET TABLES

The proposed 2024–2025 budget is presented in the following nine summary tables, of which five tables include the 2022–2023 approved budget for comparison purposes.

- **Table A - Proposed regular budget for the biennium 2024–2025:** Provides the overall proposed budget including the breakdown of budget at the level 2 objectives of the IARC Project Tree for the biennium.
- **Table B - Summary of biennial resources by level 2/3 objectives and sources of fund:** Includes financial resources overview with breakdown of budget at the level 2 and level 3 objectives of the IARC Project Tree inclusive of the proposed regular budget allocations and projected extrabudgetary resources (i.e. voluntary contributions, PSC account, and GCSF). The 2022–2023 figures are also provided for comparison.
- **Table C - Summary of regular budget by level 2/3 objectives and year:** Presents further details of the proposed regular budget allocations by year, broken down by staff and non-staff budget.
- **Table D - Summary of secured extrabudgetary resources by level 2/3 objectives and year:** Presents further details of the secured extrabudgetary resources allocations by year, broken down by staff and non-staff budget.
- **Table E - Summary of regular budget funded staff by level 2/3 objectives and staff category:** Summarizes the staff in person-years funded by regular budget, allotted to each objective at the level 2 and level 3 objectives of the IARC Project Tree in comparison with the approved figures of 2022–2023. Number of staff is grouped according to staff categories, i.e. General Service and Professional and above.
- **Table F - Summary of regular budget allocated to fundamental and emerging priorities by level 2/3 objectives:** Presents the details of the proposed regular budget allocations to fundamental and three emerging priorities.
- **Table G - Summary of regular budget by component and cause of increase/ decrease:** Presents the proposed budget by component of expenditure in comparison with the approved budget 2022–2023. The increases or decreases are classified based on two main criteria, i.e. programme requirement and cost changes.
- **Table H - Summary of regular budget and proposed financing:** Provides a summary of the proposed regular budget and proposed funding sources by year, in comparison with those approved for the 2022–2023 budget.
- **Table I - Summary of proposed financing from assessments on Participating States:** Provides the details of assessments on Participating States required to fund the proposed budget, including comparison with those approved for the 2022–2023 budget.

Summary Table A PROPOSED REGULAR BUDGET FOR THE BIENNIUM 2024-2025 (expressed in euros)		
LEVEL 2 OBJECTIVES	2024-2025 BUDGET	%
1. Describing the occurrence of cancer	4 068 890	8.36
2. Understanding the causes of cancer	9 814 842	20.16
3. Evaluating cancer prevention interventions	5 987 604	12.30
4. Synthesizing and mobilizing knowledge and strengthening global capacities in cancer science	6 628 336	13.62
5. Strengthening the Agency's leadership, governance, strategic engagement, and advocacy	5 401 722	11.10
6. Strengthening the efficiency and effectiveness of the Agency's research and collaboration	16 781 919	34.47
TOTAL BUDGET	48 683 313	100.00

Summary Table B SUMMARY OF BIENNIAL RESOURCES BY LEVEL 2/3 OBJECTIVES AND SOURCES OF FUND (expressed in euros)						
Level 2 Level 3	Level 2 Objectives Level 3 Objectives	Regular Budget		Secured Extra-Budgetary Resources (see note i)		
		2022-2023 Budget Amount	2024-2025 Budget Amount	2022-2023 Budget Amount	2024-2025 Budget Amount	
			%		%	
1	Describing the occurrence of cancer					
1.1	Improve and expand reporting of cancer data and statistics to inform global, regional, and national priorities for cancer prevention and cancer control	1 581 835	1 632 329	226 045	62 871	
1.2	Improve coverage, quality and utility of cancer registration data worldwide, with an emphasis on low and middle-income countries	668 256	697 025	36 000	220 051	
1.3	Enhance understanding of global, regional, national and subnational changes in cancer risk, including in relation to ongoing socioeconomic transitions and social inequalities	1 243 769	1 281 108	143 918	31 436	
1.4	Enhance understanding of economic consequences of cancer and cancer disparities – descriptive economics	453 826	458 428	0	0	
		3 947 686	4 068 890	405 963	314 358	
2	Understanding the causes of cancer					
2.1	Enhance understanding of new and known causes/risk factors for human cancer, including those that accompany key cancer transitions, and those related to cancer disparities, through the conduct of epidemiological studies	4 854 139	4 247 328	2 058 200	2 717 041	
2.2	Enhance understanding of and elucidate biological mechanisms of carcinogenesis relevant to environmental/lifestyle factors, including those that accompany key cancer transitions, and those related to cancer disparities, through the conduct of laboratory studies	3 005 619	3 406 434	326 350	1 696 096	
2.3	Enhance understanding of exposure sources, including those related to key cancer transitions, and those related to cancer disparities, and related pathways	1 202 061	1 303 717	885 307	1 705 967	
2.4	Enhance understanding of potential risk factors, including those that accompany key cancer transitions, and those related to cancer disparities, in under-researched populations and/or in low-and middle income countries and their interplay with the observed cancer patterns	1 443 607	857 363	182 130	332 916	
		10 505 426	9 814 842	3 451 987	6 452 020	
3	Evaluating cancer prevention interventions					
3.1	Enhance understanding of evidence-based interventions for cancer prevention and control to support their practical application, including those related to cancer disparities	1 808 223	2 441 967	651 042	4 450 915	
3.2	Enhance understanding of the efficacy and effectiveness of population-based interventions and cancer prevention programmes	1 681 474	1 815 819	787 736	459 594	
3.3	Enhance understanding about the development and application of biomarkers for early detection and outcome through translational studies	1 820 911	1 729 818	705 754	639 115	
		5 310 608	5 987 604	2 144 532	5 549 624	
4	Synthesizing and mobilizing knowledge and strengthening global capacities in cancer science					
4.1	Strengthen global knowledge and global and national capacities in cancer research and science	2 949 011	2 203 308	721 030	837 665	
4.2	Strengthen the understanding and use of tumour classification to underpin cancer diagnosis, management and research	607 142	523 451	2 205 288	2 382 220	
4.3	Strengthen global knowledge and global and national capacities to implement effective, quality assured, affordable interventions	1 001 140	1 620 848	312 395	1 054 745	
4.4	Enhance understanding of the causes of human cancer, including emerging cancer hazards, through cancer hazard evaluations of the available evidence-base by leading independent experts	1 830 760	2 280 729	0	984 025	
		6 388 053	6 628 336	3 238 713	5 258 655	
5	Strengthening the Agency's leadership, governance, strategic engagement, and advocacy					
5.1	Define the vision and implement the scientific strategy of the Agency, enabling an empowering culture, providing the framework for the fulfilment of its objectives	1 460 369	1 397 844	0	0	
5.2	Oversee the strategic direction of the Agency and the implementation of its programme with full respect of the Agency's values, ethical standards, and code of conduct	1 324 697	1 410 974	0	0	
5.3	Create and maintain key strategic engagement with stakeholders at national, regional and international organizations, and scale up resource mobilization activities	326 601	975 213	0	428 923	
5.4	Strengthen the Agency's global image, communication and outreach to stakeholders	2 073 016	1 617 691	593 836	454 102	
		5 184 683	5 401 722	593 836	883 025	
6	Strengthening the efficiency and effectiveness of the Agency's research and collaboration					
6.1	Ensure the availability of adequate laboratory and computing/statistical infrastructure to support and enhance research	4 695 816	6 641 919	855 334	988 990	
6.2	Enable strategic vision and implementation, including management of financial, human, information, and infrastructure resources, to enable and support the effective delivery of the Agency's mandate	9 339 057	10 140 000	3 960 854	3 901 675	
		14 034 873	16 781 919	4 816 188	4 890 665	
		30.93	34.47			
	TOTAL	45 371 329	48 683 313	14 651 219	23 348 347	
		100.00	100.00			

Notes:

i. Extra-budgetary resources include Voluntary Contributions secured at the time of budget submission, funding from the Programme Support Cost Account and the Governing Council Special Fund.

Summary Table C SUMMARY OF REGULAR BUDGET BY LEVEL 2/3 OBJECTIVES AND YEAR (expressed in euros)											
Level 2 Level 3	Level 2 Objectives Level 3 Objectives	2024			2025			2024-2025			
		Staff Budget	Non-Staff Budget	Total	Staff Budget	Non-Staff Budget	Total	Staff Budget	Non-Staff Budget	Total	
1	Describing the occurrence of cancer										
1.1	Improve and expand reporting of cancer data and statistics to inform global, regional, and national priorities for cancer prevention and cancer control	743 443	65 000	808 443	758 886	65 000	823 886	1 502 329	130 000	1 632 329	
1.2	Improve coverage, quality and utility of cancer registration data worldwide, with an emphasis on low and middle-income countries	292 504	50 000	342 504	304 521	50 000	354 521	597 025	100 000	697 025	
1.3	Enhance understanding of global, regional, national and subnational changes in cancer risk, including in relation to ongoing socioeconomic transitions and social inequalities	540 870	105 000	645 870	529 238	106 000	635 238	1 070 108	211 000	1 281 108	
1.4	Enhance understanding of economic consequences of cancer and cancer disparities – descriptive economics	173 943	55 000	228 943	174 485	55 000	229 485	348 428	110 000	458 428	
		1 750 760	275 000	2 025 760	1 767 130	276 000	2 043 130	3 517 890	551 000	4 068 890	
2	Understanding the causes of cancer										
2.1	Enhance understanding of new and known causes/risk factors for human cancer, including those that accompany key cancer transitions, and those related to cancer disparities, through the conduct of epidemiological studies	1 788 962	368 400	2 157 362	1 812 266	277 700	2 089 966	3 601 228	646 100	4 247 328	
2.2	Enhance understanding of and elucidate biological mechanisms of carcinogenesis relevant to environmental/lifestyle factors, including those that accompany key cancer transitions, and those related to cancer disparities, through the conduct of laboratory studies	1 517 800	176 750	1 694 550	1 536 734	175 150	1 711 884	3 054 534	351 900	3 406 434	
2.3	Enhance understanding of exposure sources, including those related to key cancer transitions, and those related to cancer disparities, and related pathways	589 362	55 600	644 962	596 355	62 400	658 755	1 185 717	118 000	1 303 717	
2.4	Enhance understanding of potential risk factors, including those that accompany key cancer transitions, and those related to cancer disparities, in under-researched populations and/or in low-and middle income countries and their interplay with the observed cancer patterns	359 204	67 250	426 454	363 659	67 250	430 909	722 863	134 500	857 363	
		4 255 328	668 000	4 923 328	4 309 014	582 500	4 891 514	8 564 342	1 250 500	9 814 842	
3	Evaluating cancer prevention interventions										
3.1	Enhance understanding of evidence-based interventions for cancer prevention and control to support their practical application, including those related to cancer disparities	985 153	229 250	1 214 403	998 314	229 250	1 227 564	1 983 467	458 500	2 441 967	
3.2	Enhance understanding of the efficacy and effectiveness of population-based interventions and cancer prevention programmes	739 428	165 500	904 928	745 391	165 500	910 891	1 484 819	331 000	1 815 819	
3.3	Enhance understanding about the development and application of biomarkers for early detection and outcome through translational studies	762 505	99 500	862 005	774 313	93 500	867 813	1 536 818	193 000	1 729 818	
		2 487 086	494 250	2 981 336	2 518 018	488 250	3 006 268	5 005 104	982 500	5 987 604	
4	Synthesizing and mobilizing knowledge and strengthening global capacities in cancer science										
4.1	Strengthen global knowledge and global and national capacities in cancer research and science	752 783	325 000	1 077 783	761 525	364 000	1 125 525	1 514 308	689 000	2 203 308	
4.2	Strengthen the understanding and use of tumour classification to underpin cancer diagnosis, management and research	237 043	23 700	260 743	239 008	23 700	262 708	476 051	47 400	523 451	
4.3	Strengthen global knowledge and global and national capacities to implement effective, quality assured, affordable interventions	682 915	133 500	816 415	687 933	116 500	804 433	1 370 848	250 000	1 620 848	
4.4	Enhance understanding of the causes of human cancer, including emerging cancer hazards, through cancer hazard evaluations of the available evidence-base by leading independent experts	988 426	148 500	1 136 926	995 303	148 500	1 143 803	1 983 729	297 000	2 280 729	
		2 661 167	630 700	3 291 867	2 683 769	652 700	3 336 469	5 344 936	1 283 400	6 628 336	
5	Strengthening the Agency's leadership, governance, strategic engagement, and advocacy										
5.1	Define the vision and implement the scientific strategy of the Agency, enabling an empowering culture, providing the framework for the fulfilment of its objectives	270 784	422 602	693 386	273 860	430 598	704 458	544 644	853 200	1 397 844	
5.2	Oversee the strategic direction of the Agency and the implementation of its programme with full respect of the Agency's values, ethical standards, and code of conduct	510 139	191 000	701 139	518 835	191 000	709 835	1 028 974	382 000	1 410 974	
5.3	Create and maintain key strategic engagement with stakeholders at national, regional and international organizations, and scale up resource mobilization activities	398 093	87 400	485 493	402 320	87 400	489 720	800 413	174 800	975 213	
5.4	Strengthen the Agency's global image, communication and outreach to stakeholders	558 204	257 145	815 349	563 572	238 770	802 342	1 121 776	495 915	1 617 691	
		1 737 220	958 147	2 695 367	1 758 587	947 768	2 706 355	3 495 807	1 905 915	5 401 722	
6	Strengthening the efficiency and effectiveness of the Agency's research and collaboration										
6.1	Ensure the availability of adequate laboratory and computing/statistical infrastructure to support and enhance research	976 601	2 408 566	3 385 167	994 153	2 262 579	3 256 732	1 970 754	4 671 165	6 641 919	
6.2	Enable strategic vision and implementation, including management of financial, human, information, and infrastructure resources, to enable and support the effective delivery of the Agency's mandate	4 025 191	995 136	5 020 327	4 088 304	1 031 369	5 119 673	8 113 495	2 026 505	10 140 000	
		5 001 792	3 403 722	8 405 514	5 082 457	3 293 948	8 376 405	10 084 249	6 697 670	16 781 919	
	TOTAL	17 893 353	6 429 819	24 323 172	18 118 975	6 241 166	24 360 141	36 012 328	12 670 985	48 683 313	

Summary Table D SUMMARY OF SECURED EXTRA-BUDGETARY RESOURCES BY LEVEL 2/3 OBJECTIVES AND YEAR (expressed in euros)										
Level 2 Level 3	Level 2 Objectives Level 3 Objectives	2024			2025			2024-2025		
		Staff Budget	Non-Staff Budget	Total	Staff Budget	Non-Staff Budget	Total	Staff Budget	Non-Staff Budget	Total
1	Describing the occurrence of cancer									
1.1	Improve and expand reporting of cancer data and statistics to inform global, regional, and national priorities for cancer prevention and cancer control	31 398	0	31 398	31 473	0	31 473	62 871	0	62 871
1.2	Improve coverage, quality and utility of cancer registration data worldwide, with an emphasis on low and middle-income countries	109 894	0	109 894	110 157	0	110 157	220 051	0	220 051
1.3	Enhance understanding of global, regional, national and subnational changes in cancer risk, including in relation to ongoing socioeconomic transitions and social inequalities	15 699	0	15 699	15 737	0	15 737	31 436	0	31 436
1.4	Enhance understanding of economic consequences of cancer and cancer disparities – descriptive economics	0	0	0	0	0	0	0	0	0
		156 991	0	156 991	157 367	0	157 367	314 358	0	314 358
2	Understanding the causes of cancer									
2.1	Enhance understanding of new and known causes/risk factors for human cancer, including those that accompany key cancer transitions, and those related to cancer disparities, through the conduct of epidemiological studies	586 105	1 039 285	1 625 390	308 181	783 470	1 091 651	894 286	1 822 755	2 717 041
2.2	Enhance understanding of and elucidate biological mechanisms of carcinogenesis relevant to environmental/lifestyle factors, including those that accompany key cancer transitions, and those related to cancer disparities, through the conduct of laboratory studies	617 737	404 499	1 022 236	507 805	166 055	673 860	1 125 542	570 554	1 696 096
2.3	Enhance understanding of exposure sources, including those related to key cancer transitions, and those related to cancer disparities, and related pathways	306 307	788 125	1 094 432	361 091	250 444	611 535	667 398	1 038 569	1 705 967
2.4	Enhance understanding of potential risk factors, including those that accompany key cancer transitions, and those related to cancer disparities, in under-researched populations and/or in low-and middle income countries and their interplay with the observed cancer patterns	155 906	16 419	172 325	160 591	0	160 591	316 497	16 419	332 916
		1 666 055	2 248 328	3 914 383	1 337 668	1 199 969	2 537 637	3 003 723	3 448 297	6 452 020
3	Evaluating cancer prevention interventions									
3.1	Enhance understanding of evidence-based interventions for cancer prevention and control to support their practical application, including those related to cancer disparities	842 951	1 570 494	2 413 445	730 798	1 306 672	2 037 470	1 573 749	2 877 166	4 450 915
3.2	Enhance understanding of the efficacy and effectiveness of population-based interventions and cancer prevention programmes	47 509	249 900	297 409	48 385	113 800	162 185	95 894	363 700	459 594
3.3	Enhance understanding about the development and application of biomarkers for early detection and outcome through translational studies	246 517	80 000	326 517	252 598	60 000	312 598	499 115	140 000	639 115
		1 136 977	1 900 394	3 037 371	1 031 781	1 480 472	2 512 253	2 168 758	3 380 866	5 549 624
4	Synthesizing and mobilizing knowledge and strengthening global capacities in cancer science									
4.1	Strengthen global knowledge and global and national capacities in cancer research and science	305 555	191 116	496 671	251 994	89 000	340 994	557 549	280 116	837 665
4.2	Strengthen the understanding and use of tumour classification to underpin cancer diagnosis, management and research	685 101	500 000	1 185 101	697 119	500 000	1 197 119	1 382 220	1 000 000	2 382 220
4.3	Strengthen global knowledge and global and national capacities to implement effective, quality assured, affordable interventions	388 948	140 304	529 252	403 603	121 890	525 493	792 551	262 194	1 054 745
4.4	Enhance understanding of the causes of human cancer, including emerging cancer hazards, through cancer hazard evaluations of the available evidence-base by leading independent experts	398 774	90 000	488 774	405 251	90 000	495 251	804 025	180 000	984 025
		1 778 378	921 420	2 699 798	1 757 967	800 890	2 558 857	3 536 345	1 722 310	5 258 655
5	Strengthening the Agency's leadership, governance, strategic engagement, and advocacy									
5.1	Define the vision and implement the scientific strategy of the Agency, enabling an empowering culture, providing the framework for the fulfilment of its objectives	0	0	0	0	0	0	0	0	0
5.2	Oversee the strategic direction of the Agency and the implementation of its programme with full respect of the Agency's values, ethical standards, and code of conduct	0	0	0	0	0	0	0	0	0
5.3	Create and maintain key strategic engagement with stakeholders at national, regional and international organizations, and scale up resource mobilization activities	214 206	0	214 206	214 717	0	214 717	428 923	0	428 923
5.4	Strengthen the Agency's global image, communication and outreach to stakeholders	175 431	50 000	225 431	178 671	50 000	228 671	354 102	100 000	454 102
		389 637	50 000	439 637	393 388	50 000	443 388	783 025	100 000	883 025
6	Strengthening the efficiency and effectiveness of the Agency's research and collaboration									
6.1	Ensure the availability of adequate laboratory and computing/statistical infrastructure to support and enhance research	189 760	298 019	487 779	197 168	304 043	501 211	386 928	602 062	988 990
6.2	Enable strategic vision and implementation, including management of financial, human, information, and infrastructure resources, to enable and support the effective delivery of the Agency's mandate	1 317 399	867 351	2 184 750	1 345 360	371 565	1 716 925	2 662 759	1 238 916	3 901 675
		1 507 159	1 165 370	2 672 529	1 542 528	675 608	2 218 136	3 049 687	1 840 978	4 890 665
	TOTAL	6 635 197	6 285 512	12 920 709	6 220 699	4 206 939	10 427 638	12 855 896	10 492 451	23 348 347

Summary Table E SUMMARY OF REGULAR BUDGET FUNDED STAFF BY LEVEL 2/3 OBJECTIVES AND STAFF CATEGORY (expressed in person years)							
Level 2 Level 3	Level 2 Objectives Level 3 Objectives	2022-2023 Staff Activity (person years)			2024-2025 Staff Activity (person years)		
		Professional and above	General Service	Total Staff	Professional and above	General Service	Total Staff
1	Describing the occurrence of cancer						
1.1	Improve and expand reporting of cancer data and statistics to inform global, regional, and national priorities for cancer prevention and cancer control	2.90	3.20	6.10	2.88	3.20	6.08
1.2	Improve coverage, quality and utility of cancer registration data worldwide, with an emphasis on low and middle-income countries	1.00	1.70	2.70	0.98	1.70	2.68
1.3	Enhance understanding of global, regional, national and subnational changes in cancer risk, including in relation to ongoing socioeconomic transitions and social inequalities	2.10	2.00	4.10	2.15	2.00	4.15
1.4	Enhance understanding of economic consequences of cancer and cancer disparities – descriptive economics	1.00	0.10	1.10	1.00	0.10	1.10
		7.00	7.00	14.00	7.00	7.00	14.00
2	Understanding the causes of cancer						
2.1	Enhance understanding of new and known causes/risk factors for human cancer, including those that accompany key cancer transitions, and those related to cancer disparities, through the conduct of epidemiological studies	8.90	9.50	18.40	7.20	7.75	14.95
2.2	Enhance understanding of and elucidate biological mechanisms of carcinogenesis relevant to environmental/lifestyle factors, including those that accompany key cancer transitions, and those related to cancer disparities, through the conduct of laboratory studies	5.80	5.85	11.65	6.30	6.50	12.80
2.3	Enhance understanding of exposure sources, including those related to key cancer transitions, and those related to cancer disparities, and related pathways	1.95	2.75	4.70	2.15	2.90	5.05
2.4	Enhance understanding of potential risk factors, including those that accompany key cancer transitions, and those related to cancer disparities, in under-researched populations and/or in low-and middle income countries and their interplay with the observed cancer patterns	2.50	2.50	5.00	1.30	1.80	3.10
		19.15	20.60	39.75	16.95	18.95	35.90
3	Evaluating cancer prevention interventions						
3.1	Enhance understanding of evidence-based interventions for cancer prevention and control to support their practical application, including those related to cancer disparities	4.40	1.95	6.35	5.25	2.35	7.60
3.2	Enhance understanding of the efficacy and effectiveness of population-based interventions and cancer prevention programmes	3.20	2.30	5.50	3.00	2.70	5.70
3.3	Enhance understanding about the development and application of biomarkers for early detection and outcome through translational studies	3.25	3.70	6.95	3.10	3.85	6.95
		10.85	7.95	18.80	11.35	8.90	20.25
4	Synthesizing and mobilizing knowledge and strengthening global capacities in cancer science						
4.1	Strengthen global knowledge and global and national capacities in cancer research and science	3.85	5.80	9.65	2.70	3.90	6.60
4.2	Strengthen the understanding and use of tumour classification to underpin cancer diagnosis, management and research	0.80	1.10	1.90	0.70	1.10	1.80
4.3	Strengthen global knowledge and global and national capacities to implement effective, quality assured, affordable interventions	1.95	1.10	3.05	3.00	2.25	5.25
4.4	Enhance understanding of the causes of human cancer, including emerging cancer hazards, through cancer hazard evaluations of the available evidence-base by leading independent experts	3.00	3.30	6.30	4.00	3.50	7.50
		9.60	11.30	20.90	10.40	10.75	21.15
5	Strengthening the Agency's leadership, governance, strategic engagement, and advocacy						
5.1	Define the vision and implement the scientific strategy of the Agency, enabling an empowering culture, providing the framework for the fulfilment of its objectives	1.00	1.00	2.00	1.00	0.60	1.60
5.2	Oversee the strategic direction of the Agency and the implementation of its programme with full respect of the Agency's values, ethical standards, and code of conduct	1.80	2.25	4.05	1.90	2.10	4.00
5.3	Create and maintain key strategic engagement with stakeholders at national, regional and international organizations, and scale up resource mobilization activities	0.30	0.55	0.85	1.30	2.10	3.40
5.4	Strengthen the Agency's global image, communication and outreach to stakeholders	4.00	2.00	6.00	3.00	1.00	4.00
		7.10	5.80	12.90	7.20	5.80	13.00
6	Strengthening the efficiency and effectiveness of the Agency's research and collaboration						
6.1	Ensure the availability of adequate laboratory and computing/statistical infrastructure to support and enhance research	1.30	9.20	10.50	1.00	9.60	10.60
6.2	Enable strategic vision and implementation, including management of financial, human, information, and infrastructure resources, to enable and support the effective delivery of the Agency's mandate	13.00	23.35	36.35	13.70	22.10	35.80
		14.30	32.55	46.85	14.70	31.70	46.40
	TOTAL	68.00	85.20	153.20	67.60	83.10	150.70

Summary Table F SUMMARY OF REGULAR BUDGET ALLOCATED TO FUNDAMENTAL AND EMERGING PRIORITIES BY LEVEL 2/3 OBJECTIVES (expressed in person-years)							
Level 2	Level 3 Objectives	Level 2 Objectives	Emerging Priorities				Total Regular Budget 2024-2025
			Fundamental Priority	Evolving cancer risk factors and populations in transition	Implementation research	Economic and societal impacts of cancer	
1	1.1 Improve and expand reporting of cancer data and statistics to inform global, regional, and national priorities for cancer prevention and cancer control 1.2 Improve coverage, quality and utility of cancer registration data worldwide, with an emphasis on low and middle-income countries 1.3 Enhance understanding of global, regional, national and subnational changes in cancer risk, including in relation to ongoing socioeconomic transitions and social 1.4 Enhance understanding of economic consequences of cancer and cancer disparities – descriptive economics	Describing the occurrence of cancer	1 445 163	81 617	23 933	81 617	1 632 330
			662 173	0	34 851	0	697 024
			803 349	42 202	0	435 557	1 281 108
			0	0	0	458 428	458 428
			2 910 685	123 819	58 784	975 602	4 068 890
2	2.1 Enhance understanding of new and known causes/risk factors for human cancer, including those that accompany key cancer transitions, and those related to cancer disparities, through the conduct of epidemiological studies 2.2 Enhance understanding of and elucidate biological mechanisms of carcinogenesis relevant to environmental/lifestyle factors, including those that accompany key cancer transitions, and those related to cancer disparities, through the conduct of laboratory studies 2.3 Enhance understanding of exposure sources, including those related to key cancer transitions, and those related to cancer disparities, and related pathways 2.4 Enhance understanding of potential risk factors, including those that accompany key cancer transitions, and those related to cancer disparities, in under-researched populations and/or in low- and middle income countries and their interplay with the observed cancer patterns	Understanding the causes of cancer	2 408 310	1 395 363	0	443 655	4 247 328
			2 251 817	983 837	0	170 780	3 406 434
			982 925	260 743	0	60 048	1 303 716
			685 125	86 119	0	86 119	857 363
			6 328 177	2 726 062	0	760 602	9 814 841
3	3.1 Enhance understanding of evidence-based interventions for cancer prevention and control to support their practical application, including those related to cancer 3.2 Enhance understanding of the efficacy and effectiveness of population-based interventions and cancer prevention programmes 3.3 Enhance understanding about the development and application of biomarkers for early detection and outcome through translational studies	Evaluating cancer prevention interventions	373 452	0	1 717 453	351 063	2 441 968
			0	0	1 815 819	0	1 815 819
			1 729 818	0	0	0	1 729 818
			2 103 270	0	3 533 272	351 063	5 987 605
4	4.1 Strengthen global knowledge and global and national capacities in cancer research and science 4.2 Strengthen the understanding and use of tumour classification to underpin cancer diagnosis, management and research 4.3 Strengthen global knowledge and global and national capacities to implement effective, quality assured, affordable interventions 4.4 Enhance understanding of the causes of human cancer, including emerging cancer hazards, through cancer hazard evaluations of the available evidence-base by leading independent experts	Synthesizing and mobilizing knowledge and strengthening global capacities in cancer science	2 203 308	0	0	0	2 203 308
			523 451	0	0	0	523 451
			1 620 848	0	0	0	1 620 848
			2 280 729	0	0	0	2 280 729
			6 628 336	0	0	0	6 628 336
5	5.1 Define the vision and implement the scientific strategy of the Agency, enabling an empowering culture, providing the framework for the fulfilment of its objectives 5.2 Oversee the strategic direction of the Agency and the implementation of its programme with full respect of the Agency's values, ethical standards, and code of 5.3 Create and maintain key strategic engagement with stakeholders at national, regional and international organizations, and scale up resource mobilization 5.4 Strengthen the Agency's global image, communication and outreach to stakeholders	Strengthening the Agency's leadership, governance, strategic engagement, and advocacy	1 397 844	0	0	0	1 397 844
			1 410 973	0	0	0	1 410 973
			975 213	0	0	0	975 213
			1 617 691	0	0	0	1 617 691
			5 401 721	0	0	0	5 401 721
6	6.1 Ensure the availability of adequate laboratory and computing/statistical infrastructure to support and enhance research 6.2 Enable strategic vision and implementation, including management of financial, human, information, and infrastructure resources, to enable and support the effective delivery of the Agency's mandate	Strengthening the efficiency and effectiveness of the Agency's research and collaboration	6 641 920	0	0	0	6 641 920
			10 140 000	0	0	0	10 140 000
			16 781 920	0	0	0	16 781 920
			40 154 109	2 849 881	3 592 056	2 087 267	48 683 313

Summary Table G SUMMARY OF REGULAR BUDGET BY COMPONENT AND CAUSE OF INCREASE/DECREASE (expressed in euros)										
COMPONENT	2022-2023 Budget			2024-2025 Budget			BIENNIAL INCREASE/(DECREASE) 2024-2025 vs 2022-2023 <i>(see below note)</i>			
	2022	2023	2022-2023	2024	2025	2024-2025	Programme	Cost	Total	%
	Staff Budget:									
Professional	10 711 819	10 733 812	21 445 631	10 919 206	11 011 305	21 930 511	(236 145)	721 025	484 880	2.26%
General Service	6 729 370	6 882 328	13 611 698	6 974 147	7 107 670	14 081 817	(252 872)	722 991	470 119	3.45%
Total Staff Costs	17 441 189	17 616 140	35 057 329	17 893 353	18 118 975	36 012 328	(489 017)	1 444 016	954 999	2.72%
Non-Staff Budget:										
Temporary assistance	54 500	54 500	109 000	175 752	216 748	392 500	283 500	0	283 500	260.09%
Temporary advisors (experts, not coming for meetings)	55 500	55 500	111 000	36 000	36 000	72 000	(39 000)	0	(39 000)	-35.14%
Other contractual arrangements (APWs, SSAs and consultants)	336 500	294 500	631 000	421 449	405 102	826 551	195 551	0	195 551	30.99%
Meetings (temporary advisors and participants)	526 000	511 500	1 037 500	396 000	440 500	836 500	(201 000)	0	(201 000)	-19.37%
Duty travel (all categories of staff including fellows)	373 100	365 100	738 200	265 475	269 475	534 950	(203 250)	0	(203 250)	-27.53%
Collaborative research agreements	111 000	103 000	214 000	132 500	132 500	265 000	51 000	0	51 000	23.83%
Supplies	64 433	63 500	127 933	161 612	143 113	304 725	176 792	0	176 792	138.19%
Equipment and furniture	162 100	114 500	276 600	137 800	133 800	271 600	(5 000)	0	(5 000)	-1.81%
Fellowships	820 500	780 500	1 601 000	933 150	779 650	1 712 800	111 800	0	111 800	6.98%
Office services	106 900	106 700	213 600	127 578	129 527	257 105	43 505	0	43 505	20.37%
Publications (including printing)	163 534	162 353	325 887	160 900	166 200	327 100	1 213	0	1 213	0.37%
Library books & periodicals	85 431	94 617	180 048	85 462	95 258	180 720	672	0	672	0.37%
Laboratory maintenance and supplies	348 250	330 250	678 500	208 750	210 250	419 000	(259 500)	0	(259 500)	-38.25%
IT maintenance and licences	76 635	72 230	148 865	590 997	356 991	947 988	799 123	0	799 123	536.81%
Building services	1 406 176	1 951 391	3 357 567	2 286 244	2 415 902	4 702 146	1 344 579	0	1 344 579	40.05%
Staff Development & Training	91 600	91 300	182 900	103 150	103 150	206 300	23 400	0	23 400	12.79%
Director's Development Provision	170 000	170 000	340 000	180 000	180 000	360 000	20 000	0	20 000	5.88%
Others	20 200	20 200	40 400	27 000	27 000	54 000	13 600	0	13 600	33.66%
Total Non-Staff Costs	4 972 359	5 341 641	10 314 000	6 429 819	6 241 166	12 670 985	2 356 985	0	2 356 985	22.85%
Unprogrammed reserve	0	0	0	0	0	0	0	0	0	0.00%
TOTAL REGULAR BUDGET	22 413 548	22 957 781	45 371 329	24 323 172	24 360 141	48 683 313	1 867 968	1 444 016	3 311 984	7.30%
							4.12%	3.18%	7.30%	

Note: Causes of budget changes are classified into two groups i.e. due to programmatic requirements ('Programme') and due to cost changes ('Cost').

Summary Table H SUMMARY OF REGULAR BUDGET AND PROPOSED FINANCING (expressed in euros)							
LEVEL 2 OBJECTIVES	2022	2023	2022-2023	2024	2025	2024-2025	
			%			%	
1. Describe the occurrence of cancer	1 964 811	1 982 875	3 947 686	2 025 760	2 043 130	4 068 890	8.36%
2. Understand the causes of cancer	5 257 612	5 247 814	10 505 426	4 923 328	4 891 514	9 814 842	20.16%
3. Evaluate and implement cancer prevention and control strategies	2 676 749	2 633 859	5 310 608	2 981 336	3 006 268	5 987 604	12.30%
4. Increase the capacity for cancer research	3 160 706	3 227 347	6 388 053	3 291 867	3 336 469	6 628 336	13.62%
5. Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research	2 634 129	2 550 554	5 184 683	2 695 367	2 706 355	5 401 722	11.10%
6. Enable and support the efficient conduct and coordination of research	6 719 541	7 315 332	14 034 873	8 405 514	8 376 405	16 781 919	34.47%
Total Regular Budget	22 413 548	22 957 781	45 371 329	24 323 172	24 360 141	48 683 313	100.00%
PROPOSED FINANCING: (see Summary Table I)							
Full financing from Participating States Assessments	22 413 548	22 957 781	45 371 329	24 323 172	24 360 141	48 683 313	100.00%

Summary Table I SUMMARY OF PROPOSED FINANCING FROM ASSESSMENTS ON 27 PARTICIPATING STATES (expressed in euros)									
Participating States	Number of units assigned (see Note 1 & 2)	YEAR 2024		YEAR 2025		BIENNIUM 2024-2025	BIENNIUM 2022-2023	2024-2025	2024-2025
		70% of the assessed budget borne equally	30% of the assessed budget in accordance with the unit system	70% of the assessed budget borne equally	30% of the assessed budget in accordance with the unit system	TOTAL	TOTAL	TOTAL	% increase/ (decrease) (see Note 3)
Australia	2	630 601	256 033	631 559	256 423	1 774 616	1 765 991	0.49	8 625
Austria	1	630 601	128 017	631 559	128 211	1 518 388	1 493 764	1.65	24 624
Belgium	1	630 601	128 017	631 559	128 211	1 518 388	1 493 764	1.65	24 624
Brazil	2	630 601	256 033	631 559	256 423	1 774 616	1 765 991	0.49	8 625
Canada	2	630 601	256 033	631 559	256 423	1 774 616	1 765 991	0.49	8 625
China	8	630 601	1 024 133	631 559	1 025 691	3 311 984	0	0.00	3 311 984
Denmark	1	630 601	128 017	631 559	128 211	1 518 388	1 493 764	1.65	24 624
Finland	0	630 601	0	631 559	0	1 262 160	1 221 536	3.33	40 624
France	4	630 601	512 065	631 559	512 846	2 287 071	2 310 448	-1.01	(23 377)
Germany	4	630 601	512 065	631 559	512 846	2 287 071	2 310 448	-1.01	(23 377)
Hungary	0	630 601	0	631 559	0	1 262 160	1 221 536	3.33	40 624
India	1	630 601	128 017	631 559	128 211	1 518 388	1 493 764	1.65	24 624
Iran (Islamic Republic of)	0	630 601	0	631 559	0	1 262 160	1 221 536	3.33	40 624
Ireland	0	630 601	0	631 559	0	1 262 160	1 221 536	3.33	40 624
Italy	2	630 601	256 033	631 559	256 423	1 774 616	1 765 991	0.49	8 625
Japan	8	630 601	1 024 133	631 559	1 025 691	3 311 984	3 399 360	-2.57	(87 376)
Morocco	0	630 601	0	631 559	0	1 262 160	1 221 536	3.33	40 624
Netherlands	1	630 601	128 017	631 559	128 211	1 518 388	1 493 764	1.65	24 624
Norway	1	630 601	128 017	631 559	128 211	1 518 388	1 493 764	1.65	24 624
Qatar	0	630 601	0	631 559	0	1 262 160	1 221 536	3.33	40 624
Republic of Korea	2	630 601	256 033	631 559	256 423	1 774 616	1 765 991	0.49	8 625
Russian Federation	1	630 601	128 017	631 559	128 211	1 518 388	1 765 991	-14.02	(247 603)
Spain	2	630 601	256 033	631 559	256 423	1 774 616	1 765 991	0.49	8 625
Sweden	1	630 601	128 017	631 559	128 211	1 518 388	1 493 764	1.65	24 624
Switzerland	1	630 601	128 017	631 559	128 211	1 518 388	1 493 764	1.65	24 624
United Kingdom	4	630 601	512 065	631 559	512 846	2 287 071	2 310 448	-1.01	(23 377)
United States of America	8	630 601	1 024 133	631 559	1 025 691	3 311 984	3 399 360	-2.57	(87 376)
TOTAL FUNDING	57	17 026 227	7 296 945	17 052 093	7 308 048	48 683 313	45 371 329	7.30	3 311 984

Notes:
1. The method of assessment of contributions of Participating States is detailed in Resolutions GC/15/R9, GC/54/R18, and GC/56/R6.
2. Group classification of countries for the purpose of assigning units in accordance with the applicable GC resolutions is based on the WHO scale of assessments as adopted by the World Health Assembly in May 2022 (Resolution WHA75.9). As a result of the change in the WHO scale of assessment, the Russian Federation moves from Group 3 to Group 4 for the purpose of calculation of its assessed contribution for 2024-2025.
3. Full contribution from China allows 7.30% increase in the regular budget and the overall assessed contributions from Participating States for 2024-2025. The overall assessment of remaining 26 Participating States (i.e. excluding China) remains the same as the 2022-2023 budget.

ANNEXES

Five additional tables are also provided hereafter as supplementary information:

- **Information Table 1 - Total staff and non-staff budget by Branch:** Provides details of annual allocation of staff and non-staff budget by Branch.
- **Information Table 2 - IARC Project Tree structure and associated projects:** Shows the structure of the IARC Project Tree from the highest level objective (level 1) to the most detailed level objectives (level 3) and associated projects contributing to the respective Project Tree path.
- **Information Table 3 - Comparison of proposed regular budget 2024–2025 with approved regular budget 2022–2023 by level 2/3 objectives:** Provides supplementary information to Summary Table B for comparison of the proposed budget 2024–2025 with the approved budget 2022–2023 in equivalent categories of objectives.
- **Information Table 4 - Group classification of countries and assigning units for assessed contributions:** Provides supplementary information to the Summary Table I for comparison of the group classification and unit assignment of IARC Participating States in the proposed budget 2024–2025 with three prior approved biennial budgets.
- **Information Table 5 - United Nations accounting rates of exchange: euros to US dollars:** Contains the monthly exchange rates set by the United Nations for euros to US dollars from January 2012 to December 2022.

Information Table 1 TOTAL STAFF AND NON-STAFF BUDGET BY PILLAR AND BRANCH (REGULAR BUDGET ONLY) (expressed in euros)										
Pillar and Branch	Number of Posts	2024		2025		Total 2024-2025				
		Staff Budget	Non-staff Budget	Total Budget	Staff Budget	Non-staff Budget	Total Budget			
SCIENTIFIC PROGRAMME										
I. Data for action										
CSU Cancer Surveillance	14.00	1 750 760	275 000	2 025 760	1 767 130	276 000	2 043 130	3 517 890	551 000	4 068 890
II. Understanding the causes										
GEM Genomic Epidemiology	14.00	1 735 220	292 250	2 027 470	1 755 821	198 750	1 954 571	3 491 041	491 000	3 982 041
NME Nutrition and Metabolism ⁽¹⁾	19.90	2 244 908	410 000	2 654 908	2 272 932	410 000	2 682 932	4 517 840	820 000	5 337 840
III. From understanding to prevention										
ENV Environment and Lifestyle Epidemiology	8.40	1 024 207	197 500	1 221 707	1 037 272	197 500	1 234 772	2 061 479	395 000	2 456 479
EGM Epigenomics and Mechanisms	13.00	1 405 537	167 000	1 572 537	1 427 617	151 000	1 578 617	2 833 154	318 000	3 151 154
EPR Early Detection, Prevention and Infections	13.00	1 683 118	399 000	2 082 118	1 702 046	399 000	2 101 046	3 385 164	798 000	4 183 164
IV. Knowledge mobilization										
ESC Evidence Synthesis and Classification	11.50	1 517 986	269 500	1 787 486	1 528 671	269 500	1 798 171	3 046 657	539 000	3 585 657
LCB Learning and Capacity Building	4.00	410 679	298 000	708 679	415 737	338 000	753 737	826 416	636 000	1 462 416
LEADERSHIP, GOVERNANCE, STRATEGIC ENGAGEMENT AND ADVOCACY										
DIR Office of the Director ⁽²⁾	7.80	1 029 356	533 002	1 562 358	1 042 605	540 998	1 583 603	2 071 961	1 074 000	3 145 961
ADMINISTRATIVE PROGRAMME										
SSR Services to Science and Research	45.10	5 091 582	3 588 567	8 680 149	5 169 145	3 460 418	8 629 563	10 260 727	7 048 985	17 309 712
TOTAL	150.70	17 893 353	6 429 819	24 323 172	18 118 975	6 241 166	24 360 141	36 012 328	12 670 985	48 683 313

Note: 1. Budget for NME includes the budget for Laboratory Support and Services (LSB) that provide supports also to other Branches.
2. Office of the Director includes also the Ethic and Compliance Office, Strategic Engagement and Outreach.

Information Table 2							
IARC PROJECT TREE STRUCTURE AND ASSOCIATED PROJECTS IN 2024–2025							
LEVEL 1 OBJECTIVE: To reduce the burden and suffering from cancer today and among future generations							
Level 2 Objectives Level 3 Objectives	Project Number	Project Title	% Contribute to Fundamental Priority	% Contribute to Evolving cancer risk factors and populations in transition	% Contribute to Emerging Priorities	Economic and societal impacts of cancer	
							Implementation research
1 Describing the occurrence of cancer	PB.2425.CSU.01	Global cancer indicators: expansion and innovation	90	5	-	5	
	PB.2425.CSU.04	Childhood cancer	85	5	5	5	
	PB.2425.CSU.02	Accelerating cancer registry support and development	95	-	5	-	
	PB.2425.CSU.03	Descriptive epidemiology of cancer	90	5	-	5	
	PB.2425.CSU.06	Social inequalities and cancer	10	-	-	90	
	PB.2425.CSU.05	Economics of cancer	-	-	-	100	
	2 Understanding the causes of cancer	PB.2425.EGM.01	Epigenetic markers of childhood cancer risk & their environmental determinants	70	30	-	-
		PB.2425.EGM.05	Molecular epidemiology studies on mechanisms in cancer etiology & biomarkers of risk and prevention implementation	30	70	-	-
		PB.2425.ENV.01	To investigate environmental and lifestyle causes of cancer	60	30	-	10
		PB.2425.ENV.02	To study the epidemiology of cancers associated with known and suspected carcinogens in the occupational setting	50	30	-	20
		PB.2425.ENV.03	To study cancers associated with exposure to low doses of ionising radiation	60	30	-	10
		PB.2425.GEM.01	Understanding genetic susceptibility of cancer	60	40	-	-
		PB.2425.NME.06	Novel lifestyle exposures and interventions to enhance understanding of cancer	70	20	-	10
		PB.2425.NME.08	Dietary and lifestyle exposures associated with cancer co-morbidity	50	20	-	30
PB.2425.EGM.03		Epigenetic driver genes in cancer and their link to environmental carcinogens using pan-cancer multi-omics approach	60	40	-	-	
PB.2425.EGM.04		Toxico-epigenomic impact and molecular markers of cancer risk agents in experimental models and humans	70	30	-	-	
2.2 Enhance understanding of and elucidate biological mechanisms of carcinogenesis relevant to environmental/lifestyle factors, including those that accompany key cancer transitions, and those related to cancer disparities, through the conduct of laboratory studies	PB.2425.GEM.02	Studying causes of cancer using genomic techniques	60	40	-	-	
	PB.2425.GEM.05	Somatic Cancer Genomics: molecular characterization of cancer	70	10	-	20	
	PB.2425.NME.04	Studies on the role of hormones and metabolism in cancer etiology	70	30	-	-	
	PB.2425.NME.05	Metabolomics-based epidemiologic studies on cancer aetiology and mechanisms	80	20	-	-	
	PB.2425.NME.09	Investigating etiological risk factors for the development of colorectal cancer	70	20	-	10	
	2.3 Enhance understanding of exposure sources, including those related to key cancer transitions, and those related to cancer disparities, and related pathways	PB.2425.EPR.08	Improving estimates of infection-attributable cancer burden: a focus on Epstein-Barr virus	100	-	-	-
		PB.2425.GEM.06	Project Title: Understand variations in cancer incidence and survival	70	15	-	15
	2.4 Enhance understanding of potential risk factors, including those that accompany key cancer transitions, and those related to cancer disparities, in under-researched populations and/or in low- and middle income countries and their interplay with the observed cancer patterns						

Information Table 2							
IARC PROJECT TREE STRUCTURE AND ASSOCIATED PROJECTS IN 2024-2025							
LEVEL 1 OBJECTIVE: To reduce the burden and suffering from cancer today and among future generations							
Level 2 Objectives Level 3 Objectives	Project Number	Project Title	% Contribute to Fundamental Priority	% Contribute to Emerging Priorities	Evolving cancer risk factors and populations in transition	Implementation research	Economic and societal impacts of cancer
3 Evaluating cancer prevention interventions							
3.1 Enhance understanding of evidence-based interventions for cancer prevention and control to support their practical application, including those related to cancer disparities	PB-2425.EW.04	To identify barriers to improving survival of common curable cancers in LMICs	-	-	-	80	20
	PB-2425.EPR.01	Strengthening national capacities to improve quality assurance on cancer screening programmes	30	-	-	60	10
	PB-2425.EPR.02	Evaluation of multi-level interventions to tackle inequalities on cancer	20	-	-	60	20
	PB-2425.EPR.03	Evaluating implementation of innovative solutions for cancer prevention & early detection including screening for new si	20	-	-	60	20
	PB-2425.EPR.09	Helicobacter pylori (HP) infection and gastric cancer (GC) – from aetiology to implementation research	-	-	-	100	-
3.2 Enhance understanding of the efficacy and effectiveness of population-based interventions and cancer prevention programmes	PB-2425.EPR.04	Cervical cancer prevention in low- and middle-income countries	-	-	-	100	-
	PB-2425.EPR.05	Implementation research for cervical cancer elimination and prevention of other cancers	-	-	-	100	-
	PB-2425.EPR.06	Hepatitis viruses elimination and mortality impact evaluation	-	-	-	100	-
	PB-2425.EPR.07	Public Health Decision Modelling (PHDM)	-	-	-	100	-
3.3 Enhance understanding about the development and application of biomarkers for early detection and outcome through translational studies	PB-2425.EGM.02	Epigenetic biomarkers of exposure/cancer risk in human populations and test their reversibility by changes in lifestyle	100	-	-	-	-
	PB-2425.EGM.06	Role of infectious agents in human cancers	100	-	-	-	-
	PB-2425.GEM.03	Early cancer detection to reduce mortality and morbidity	100	-	-	-	-
4 Synthesizing and mobilizing knowledge and strengthening global capacities in cancer science							
4.1 Strengthen global knowledge and national capacities in cancer research and science	PB-2425.ESC.03	IARC Collaboration for Cancer Classification and Research	100	-	-	-	-
	PB-2425.GEM.04	Building global capacity for cancer science	100	-	-	-	-
	PB-2425.LCB.01	IARC Research Training and Fellowship Programme	100	-	-	-	-
	PB-2425.LCB.02	IARC Courses Programme	100	-	-	-	-
4.2 Strengthen the understanding and use of tumour classification to underpin cancer diagnosis, management and research	PB-2425.ESC.01	WHO classification of tumours 5th series	100	-	-	-	-
4.3 Strengthen global knowledge and national capacities to implement effective, quality assured, affordable interventions	PB-2425.EW.05	Research evidence translation	100	-	-	-	-
	PB-2425.ESC.04	IARC Handbooks of Cancer Prevention	100	-	-	-	-
	PB-2425.NMIE.03	Biobank Research, Capacity Building and Biobank Infrastructure support globally					
4.4 Enhance understanding of the causes of human cancer, including emerging cancer hazards, through cancer hazard evaluations of the available evidence-base by leading independent experts	PB-2425.NMIE.07	Integration of lifestyle and molecular exposures in statistical models for	100	-	-	-	-
	PB-2425.ESC.05	IARC Monographs on the Identification of Carcinogenic Hazards to Humans	100	-	-	-	-

Information Table 2						
IARC PROJECT TREE STRUCTURE AND ASSOCIATED PROJECTS IN 2024–2025						
LEVEL 1 OBJECTIVE: To reduce the burden and suffering from cancer today and among future generations						
Level 2 Objectives Level 3 Objectives	Project Number	Project Title	% Contribute to Fundamental Priority	% Contribute to Emerging Priorities		
				Evolving cancer risk factors and populations in transition	Implementation research	Economic and societal impacts of cancer
5 Strengthening the Agency's leadership, governance, strategic engagement, and advocacy						
5.1 Define the vision and implement the scientific strategy of the Agency, enabling an empowering culture, providing the framework for the fulfillment of its objectives	PB.2425.DIR.01	Direction and strategic leadership	100	-	-	-
5.2 Oversee the strategic direction of the Agency and the implementation of its programme with full respect of the Agency's values, ethical standards, and code of conduct	PB.2425.DIR.02	Governance and ethics	100	-	-	-
	PB.2425.SSR.01	Support to Governing and Scientific Council meetings and interactions with Participating States	100	-	-	-
5.3 Create and maintain key strategic engagement with stakeholders at national, regional and international organizations, and scale up resource mobilization activities	PB.2425.DIR.03	Strategic engagement and external relations (SEE)	100	-	-	-
5.4 Strengthen the Agency's global image, communication and outreach to stakeholders	PB.2425.SSR.04	Publishing, Library and Web-Services	100	-	-	-
6 Strengthening the efficiency and effectiveness of the Agency's research and collaboration						
6.1 Ensure the availability of adequate laboratory and computing/statistical infrastructure to support and enhance research	PB.2425.ESC.02	IARC Histopathology Laboratory	100	-	-	-
	PB.2425.IME.01	Management of IARC biobank and pre-analytical processing services	100	-	-	-
	PB.2425.IME.02	Laboratory services support	100	-	-	-
	PB.2425.SSR.03	Ensure the availability of adequate laboratory and computing/statistical infrastructure to support and enhance research	100	-	-	-
6.2 Enable strategic vision and implementation, including management of financial, human, information, and infrastructure resources, to enable and support the effective delivery of the Agency's mandate	PB.2425.SSR.02	Sound management of financial, human, information and infrastructure resources	100	-	-	-

Information Table 3 COMPARISON OF PROPOSED REGULAR BUDGET 2024-2025 WITH APPROVED REGULAR BUDGET 2022-2023 BY LEVEL 2 / 3 OBJECTIVES (expressed in euros)									
Level 2	Level 3 Objectives	REGULAR BUDGETARY RESOURCES 2024-2025		REGULAR BUDGETARY RESOURCES 2022-2023		Increase/(Decrease) Staff Budget	Non-staff Budget	Total	% Change
		Staff Budget	Total	Staff Budget	Total				
1	Describing the occurrence of cancer								
1.1	Improve and expand reporting of cancer data and statistics to inform global, regional, and national priorities for cancer prevention and cancer control	1 502 329	1 632 329	1 441 835	1 581 835	60 494	(10 000)	50 494	3.19
1.2	Improve coverage, quality and utility of cancer registration data worldwide, with an emphasis on low and middle-income countries	597 025	697 025	568 256	668 256	28 769	0	28 769	4.31
1.3	Enhance understanding of global, regional, national and subnational changes in cancer risk, including in relation to ongoing socioeconomic transitions and social inequalities	1 070 108	1 281 108	1 023 769	1 243 769	46 339	(9 000)	37 339	3.00
1.4	Enhance understanding of economic consequences of cancer and cancer disparities – descriptive economics	348 428	458 428	333 826	453 826	14 602	(10 000)	4 602	1.01
		3 517 890	4 088 890	3 367 686	3 947 686	150 204	(29 000)	121 204	3.01
2	Understanding the causes of cancer								
2.1	Enhance understanding of new and known causes/risk factors for human cancer, including those that accompany key cancer transitions, and those related to cancer disparities, through the conduct of epidemiological studies	3 601 228	4 247 328	4 325 639	4 854 139	(724 411)	117 600	(606 811)	-12.50
2.2	Enhance understanding of and elucidate biological mechanisms of carcinogenesis relevant to environmental/lifestyle factors, including those that accompany key cancer transitions, and those related to cancer disparities, through the conduct of laboratory studies	3 054 534	3 406 434	2 672 419	3 005 619	382 115	18 700	400 815	13.34
2.3	Enhance understanding of exposure sources, including those related to key cancer transitions, and those related to cancer disparities, and related pathways	1 185 717	1 303 717	1 091 261	1 202 061	94 456	7 200	101 656	8.46
2.4	Enhance understanding of potential risk factors, including those that accompany key cancer transitions, and those related to cancer disparities, in under-researched populations and/or in low-and middle income countries and their interplay with the observed cancer patterns	722 863	857 363	1 200 607	1 443 607	(477 744)	(108 500)	(586 244)	-40.61
		8 564 342	9 814 842	9 289 926	10 505 426	(725 584)	35 000	(690 584)	-5.98
3	Evaluating cancer prevention interventions								
3.1	Enhance understanding of evidence-based interventions for cancer prevention and control to support their practical application, including those related to cancer disparities	1 983 467	2 441 967	1 552 223	1 808 223	431 244	202 500	633 744	35.05
3.2	Enhance understanding of the efficacy and effectiveness of population-based interventions and cancer prevention programmes	1 484 819	1 815 819	1 378 474	1 681 474	106 345	28 000	134 345	7.99
3.3	Enhance understanding about the development and application of biomarkers for early detection and outcome through translational studies	1 536 818	1 729 818	1 576 411	1 820 911	(39 593)	(51 500)	(91 093)	-5.00
		5 005 104	5 987 604	4 507 108	5 310 608	497 996	179 000	676 996	13.32
4	Synthesizing and mobilizing knowledge and strengthening global capacities in cancer science								
4.1	Strengthen global knowledge and global and national capacities in cancer research and science	1 514 308	2 203 308	2 106 011	2 949 011	(591 703)	(154 000)	(745 703)	-25.29
4.2	Strengthen the understanding and use of tumour classification to underpin cancer diagnosis, management and research	476 051	523 451	507 042	607 142	(30 991)	(52 700)	(83 691)	-13.78
4.3	Strengthen global knowledge and global and national capacities to implement effective, quality assured, affordable interventions	1 370 848	1 620 848	759 140	1 001 140	611 708	8 000	619 708	61.90
4.4	Enhance understanding of the causes of human cancer, including emerging cancer hazards, through cancer hazard evaluations of the available evidence-base by leading independent experts	1 983 729	2 280 729	1 505 660	1 830 760	478 069	(28 100)	449 969	24.58
		5 344 936	6 628 336	4 877 853	6 388 053	467 083	(226 800)	240 283	4.55
5	Strengthening the Agency's leadership, governance, strategic engagement, and advocacy								
5.1	Define the vision and implement the scientific strategy of the Agency, enabling an empowering culture, providing the framework for the fulfilment of its objectives	544 644	1 397 844	588 369	1 460 369	(43 725)	(18 800)	(62 525)	-4.28
5.2	Oversee the strategic direction of the Agency and the implementation of its programme with full respect of the Agency's values, ethical standards, and code of conduct	1 028 974	1 410 974	960 697	1 324 697	68 277	18 000	86 277	6.51
5.3	Create and maintain key strategic engagement with stakeholders at national, regional and international organizations, and scale up resource mobilization activities	800 413	1 748 000	227 601	326 601	572 812	75 800	648 612	198.59
5.4	Strengthen the Agency's global image, communication and outreach to stakeholders	1 121 776	1 617 691	1 541 216	2 073 016	(419 440)	(35 885)	(455 325)	-21.96
		3 495 807	5 405 515	3 317 883	5 186 683	177 924	39 115	217 039	4.03
6	Strengthening the efficiency and effectiveness of the Agency's research and collaboration								
6.1	Ensure the availability of adequate laboratory and computing/statistical infrastructure to support and enhance research	1 970 754	6 641 919	1 915 145	2 780 671	55 609	1 890 494	1 946 103	41.44
6.2	Enable strategic vision and implementation, including management of financial, human, information, and infrastructure resources, to enable and support the effective delivery of the Agency's mandate	8 113 495	10 140 000	7 781 728	9 339 057	331 767	469 176	800 943	8.58
		10 084 249	16 781 919	9 696 873	14 034 873	387 376	2 359 670	2 747 046	20.33
	TOTAL	36 012 328	48 683 313	35 057 329	45 371 329	954 999	2 356 985	3 311 984	7.30

Information Table 4 GROUP CLASSIFICATION OF COUNTRIES AND ASSIGNING UNITS FOR ASSESSED CONTRIBUTIONS From 2018 to 2024											
Participating State	SCALE for 2024-2025 PROPOSED BUDGET		SCALE for 2022-2023 APPROVED BUDGET		SCALE for 2020-2021 APPROVED BUDGET		SCALE for 2018-2019 APPROVED BUDGET				
	WHO's % Contribution (WHA75.9)	IARC Group	WHO's % Contribution (WHA72.12)	IARC Group	WHO's % Contribution (WHA72.12)	IARC Group	WHO's % Contribution (WHA70.9)	IARC Group			
Australia	2.1111	3	2.2101	3	2.2101	3	2.3371	3			
Austria	0.6790	4	0.6770	4	0.6770	4	0.7201	4			
Belgium	0.8281	4	0.8211	4	0.8211	4	0.8851	4			
Brazil	2.0131	3	2.9482	3	2.9482	3	3.8232	3			
Canada	2.6282	3	2.7342	3	2.7342	3	2.9211	3			
China	15.2550	1	12.0058	1	12.0058	1	7.9212	2			
Denmark	0.5530	4	0.5540	4	0.5540	4	0.5840	4			
Finland	0.4170	5	0.4210	5	0.4210	5	0.4560	5			
France	4.3183	2	4.4273	2	4.4273	2	4.8592	2			
Germany	6.1114	2	6.0904	2	6.0904	2	6.3892	2			
Hungary	0.2280	5	0.2060	5	0.2060	5	0.1610	5			
India	1.0441	4	0.8341	4	0.8341	4	0.7370	4			
Iran (Islamic Republic of)	0.3710	5	0.3980	5	0.3980	5	0.4710	5			
Ireland	0.4390	5	0.3710	5	0.3710	5	0.3350	5			
Italy	3.1892	3	3.3072	3	3.3072	3	3.7482	3			
Japan	8.0335	1	8.5645	1	8.5645	1	9.6802	1			
Morocco	0.0550	5	0.0550	5	0.0550	5	0.0540	5			
Netherlands	1.3771	4	1.3561	4	1.3561	4	1.4821	4			
Norway	0.6790	4	0.7540	4	0.7540	4	0.8491	4			
Oatar	0.2690	5	0.2820	5	0.2820	5	0.2690	5			
Republic of Korea	2.5742	3	2.2671	3	2.2671	3	2.0391	3			
Russian Federation	1.8661	4	2.4052	3	2.4052	3	3.0882	3			
Spain	2.1341	3	2.1461	3	2.1461	3	2.4431	3			
Sweden	0.8711	4	0.9061	4	0.9061	4	0.9561	4			
Switzerland	1.1341	4	1.1511	4	1.1511	4	1.1401	4			
United Kingdom of Great Britain and Northern Ireland	4.3753	2	4.5673	2	4.5673	2	4.4632	2			
United States of America	22.0000	1	22.0000	1	22.0000	1	22.0000	1			

GROUP CLASSIFICATION OF COUNTRIES AS PER RESOLUTION GC/15/R9	
WHO's % Contribution	IARC Scale (# units)
8% and above	8
4% and above; below 8%	4
2% and above; below 4%	3
0.5% and above; below 2%	1
less than 0.5%	0

GROUP AND UNIT ASSIGNED TO EACH PARTICIPATING STATE

Information Table 5												
UNITED NATIONS ACCOUNTING RATES OF EXCHANGE: EUROS TO US DOLLARS												
From January 2012 to December 2022												
	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	
January	0.774	0.754	0.725	0.850	0.922	0.956	0.837	0.871	0.909	0.822	0.876	
February	0.763	0.737	0.737	0.882	0.882	0.937	0.805	0.876	0.907	0.824	0.878	
March	0.746	0.773	0.731	0.943	0.895	0.937	0.815	0.891	0.884	0.837	0.913	
April	0.753	0.783	0.727	0.923	0.887	0.942	0.810	0.887	0.916	0.853	0.920	
May	0.755	0.764	0.723	0.904	0.882	0.921	0.828	0.897	0.921	0.826	0.947	
June	0.805	0.767	0.735	0.894	0.897	0.893	0.848	0.899	0.879	0.820	0.958	
July	0.804	0.767	0.736	0.905	0.901	0.879	0.864	0.880	0.880	0.838	0.996	
August	0.816	0.754	0.748	0.915	0.895	0.847	0.875	0.894	0.849	0.841	0.965	
September	0.797	0.755	0.759	0.889	0.897	0.832	0.858	0.910	0.844	0.847	0.997	
October	0.777	0.737	0.787	0.891	0.906	0.848	0.865	0.914	0.852	0.860	1.032	
November	0.772	0.726	0.803	0.912	0.920	0.861	0.880	0.900	0.851	0.872	0.972	
December	0.770	0.736	0.820	0.914	0.942	0.844	0.879	0.909	0.837	0.888	0.938	
Annual Average	0.778	0.754	0.753	0.902	0.902	0.891	0.847	0.894	0.877	0.844	0.949	
Biennial Average		0.766		0.827	0.897			0.871		0.861		
		2012/2013		2014/2015	2016/2017			2018/2019		2020/2021		
Budget 2012/2013 approved at 0.675 €/US\$				Budget 2016/2017 approved at 0.729 €/US\$				Budget 2020/2021 approved at 0.819 €/US\$				
Budget 2014/2015 approved at 0.758 €/US\$				Budget 2018/2019 approved at 0.894 €/US\$				Budget 2022/2023 approved at 0.907 €/US\$				